BACKGROUND AND AIMS: Chronic alcohol drinking is a major risk factor for alcohol-associated liver disease (ALD). FK506-binding protein 51 (FKBP5), a cochaperone protein, is involved in many key regulatory pathways. It is known to be involved in stress-related disorders, but there are no reports regarding its role in ALD. This present study aimed to examine the molecular mechanism of FKBP5 in ALD. APPROACH AND RESULTS: We found a significant increase in hepatic FKBP5 transcripts and protein expression in patients with ALD and mice fed with chronic-plus-single binge ethanol. Loss of Fkbp5 in mice protected against alcohol-induced hepatic steatosis and inflammation. Transcriptomic analysis revealed a significant reduction of Transcriptional enhancer factor TEF-1 (TEA) domain transcription factor 1 (Tead1) and chemokine (C-X-C motif) ligand 1 (Cxcl1) mRNA in ethanol-fed Fkbp5-/- mice. Ethanol-induced Fkbp5 expression was secondary to down-regulation of methylation level at its 5' untranslated promoter region. The increase in Fkbp5 expression led to induction in transcription factor TEAD1 through Hippo signaling pathway. Fkbp5 can interact with yes-associated protein (YAP) upstream kinase, mammalian Ste20-like kinase 1 (MST1), affecting its ability to phosphorylate YAP and the inhibitory effect of hepatic YAP phosphorylation by ethanol leading to YAP nuclear translocation and TEAD1 activation. Activation of TEAD1 led to increased expression of its target, CXCL1, a chemokine-mediated neutrophil recruitment, causing hepatic inflammation and neutrophil infiltration in our mouse model. CONCLUSIONS: We identified an FKBP5-YAP-TEAD1-CXCL1 axis in the pathogenesis of ALD. Loss of FKBP5 ameliorates alcohol-induced liver injury through the Hippo pathway and CXCL1 signaling, suggesting its potential role as a target for the treatment of ALD.
BACKGROUND AND AIMS: Chronic alcohol drinking is a major risk factor for alcohol-associated liver disease (ALD). FK506-binding protein 51 (FKBP5), a cochaperone protein, is involved in many key regulatory pathways. It is known to be involved in stress-related disorders, but there are no reports regarding its role in ALD. This present study aimed to examine the molecular mechanism of FKBP5 in ALD. APPROACH AND RESULTS: We found a significant increase in hepatic FKBP5 transcripts and protein expression in patients with ALD and mice fed with chronic-plus-single binge ethanol. Loss of Fkbp5 in mice protected against alcohol-induced hepatic steatosis and inflammation. Transcriptomic analysis revealed a significant reduction of Transcriptional enhancer factor TEF-1 (TEA) domain transcription factor 1 (Tead1) and chemokine (C-X-C motif) ligand 1 (Cxcl1) mRNA in ethanol-fed Fkbp5-/- mice. Ethanol-induced Fkbp5 expression was secondary to down-regulation of methylation level at its 5' untranslated promoter region. The increase in Fkbp5 expression led to induction in transcription factor TEAD1 through Hippo signaling pathway. Fkbp5 can interact with yes-associated protein (YAP) upstream kinase, mammalian Ste20-like kinase 1 (MST1), affecting its ability to phosphorylate YAP and the inhibitory effect of hepatic YAP phosphorylation by ethanol leading to YAP nuclear translocation and TEAD1 activation. Activation of TEAD1 led to increased expression of its target, CXCL1, a chemokine-mediated neutrophil recruitment, causing hepatic inflammation and neutrophil infiltration in our mouse model. CONCLUSIONS: We identified an FKBP5-YAP-TEAD1-CXCL1 axis in the pathogenesis of ALD. Loss of FKBP5 ameliorates alcohol-induced liver injury through the Hippo pathway and CXCL1 signaling, suggesting its potential role as a target for the treatment of ALD.
Authors: Linda Yang; Fumiko Isoda; Kelvin Yen; Steven P Kleopoulos; William Janssen; Xiaoning Fan; Jason Mastaitis; Ambrose Dunn-Meynell; Barry Levin; Rory McCrimmon; Robert Sherwin; Sergei Musatov; Charles V Mobbs Journal: Am J Physiol Endocrinol Metab Date: 2012-02-07 Impact factor: 4.310
Authors: Cheryl L Storer; Chad A Dickey; Mario D Galigniana; Theo Rein; Marc B Cox Journal: Trends Endocrinol Metab Date: 2011-08-31 Impact factor: 12.015
Authors: Ulrike Schmidt; Dominik R Buell; Irina A Ionescu; Nils C Gassen; Florian Holsboer; Marc B Cox; Bozidar Novak; Christine Huber; Jakob Hartmann; Mathias V Schmidt; Chadi Touma; Theo Rein; Leonie Herrmann Journal: Psychoneuroendocrinology Date: 2014-11-11 Impact factor: 4.905
Authors: Robin D Clugston; Hongfeng Jiang; Man Xia Lee; Roseann Piantedosi; Jason J Yuen; Rajasekhar Ramakrishnan; Michael J Lewis; Max E Gottesman; Li-Shin Huang; Ira J Goldberg; Paul D Berk; William S Blaner Journal: J Lipid Res Date: 2011-08-19 Impact factor: 5.922
Authors: Gianluigi Guidotti; Francesca Calabrese; Christoph Anacker; Giorgio Racagni; Carmine M Pariante; Marco A Riva Journal: Neuropsychopharmacology Date: 2012-11-21 Impact factor: 7.853
Authors: Hang Zhou; Julia M Sealock; Sandra Sanchez-Roige; Toni-Kim Clarke; Daniel F Levey; Zhongshan Cheng; Boyang Li; Renato Polimanti; Rachel L Kember; Rachel Vickers Smith; Johan H Thygesen; Marsha Y Morgan; Stephen R Atkinson; Mark R Thursz; Mette Nyegaard; Manuel Mattheisen; Anders D Børglum; Emma C Johnson; Amy C Justice; Abraham A Palmer; Andrew McQuillin; Lea K Davis; Howard J Edenberg; Arpana Agrawal; Henry R Kranzler; Joel Gelernter Journal: Nat Neurosci Date: 2020-05-25 Impact factor: 24.884
Authors: Katarzyna A Ellsworth; Bruce W Eckloff; Liang Li; Irene Moon; Brooke L Fridley; Gregory D Jenkins; Erin Carlson; Abra Brisbin; Ryan Abo; William Bamlet; Gloria Petersen; Eric D Wieben; Liewei Wang Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240